U.S. President Donald Trump has signed an executive order to accelerate the review process and increase funding for research into psychedelic drugs, such as psilocybin and MDMA, for medical treatments. This initiative responds to advocacy from influential figures like podcaster Joe Rogan and aims to explore the therapeutic potential of these substances, particularly for mental health conditions like post-traumatic stress disorder (PTSD) and severe depression. Currently, most psychedelics are classified as Schedule I controlled substances, indicating they have no accepted medical use and a high potential for abuse. The order signals a shift towards understanding the medical applications of these drugs, which are administered under medical supervision in limited sessions. Notably, psilocybin has shown promise in trials for treatment-resistant depression, with some candidates like Compass Pathways' COMP360 expected to submit new drug applications to the FDA by late 2026. However, the use of these drugs carries risks, including acute anxiety and potential long-term negative effects, particularly for individuals with certain mental health disorders. The focus remains on regulated medical use rather than recreational legalization, with guidance expected from the U.S. Food and Drug Administration.